DGAP-News: Press Release 4SC AG: Henkel and 4SC Discovery start research collaboration in compound screening
(firmenpresse) - DGAP-News: 4SC AG / Key word(s): Alliance/Miscellaneous
Press Release 4SC AG: Henkel and 4SC Discovery start research
collaboration in compound screening
02.04.2012 / 07:30
---------------------------------------------------------------------
Press Release
Henkel and 4SC Discovery start research collaboration in compound screening
Planegg-Martinsried, 2 April 2012 - The biotechnology company 4SC AG
(Frankfurt, Prime Standard: VSC) today announced that its subsidiary 4SC
Discovery GmbH, which specialises in the research and discovery of novel
compounds, has entered into a research collaboration with Henkel KGaA,
Düsseldorf, in the area of compound screening. The aim of the joint
research project is to identify new and more effective laundry detergent
ingredients. For its part, 4SC Discovery will perform property calculations
on several million substances. Henkel will then use application testing to
determine the substances most suitable for new detergent formulations.
Within the partnership, 4SC Discovery will utilise the high-performance
computerised screening method that it has successfully deployed for several
years to identify potent new therapeutic compounds for the pharmaceuticals
sector. The bundling of Henkel's expertise in formulating sustainable
laundry detergents and cleaning agents with 4SC's skills in researching and
optimising new compounds is intended to make solutions available that would
remain inaccessible to simple, experience-based development strategies. In
addition, the partnership should accelerate the process for early-stage
compound discovery and optimisation and achieve greater cost efficiency
than conventional approaches.
Dr. Daniel Vitt, Managing Director of 4SC Discovery GmbH and Chief
Scientific Officer at 4SC AG, comments: 'We have successfully deployed our
computerised screening process for drug discovery and compound research
optimisation in the pharmaceutical area for many years. Now this
partnership with Henkel demonstrates large new opportunities, as it is the
first time our procedure will be used to drive the rapid and efficient
development of new detergent compounds. We intend to use the income
generated from this and future similar research collaborations with
pharmaceutical, biotech and chemical partners to further strengthen the
business of both 4SC Discovery and the 4SC Group as a whole.'
Dr. Ulrich Dauer, Chief Executive Officer of 4SC AG, adds: 'We are proud
that, only three months after launching its operations, our research
subsidiary 4SC Discovery has entered into a research collaboration with
such a renowned partner. The main focus of 4SC AG - the Group parent
company - continues to be the clinical development of its drug candidates,
however the initial success of 4SC Discovery is exciting for the whole
organization.'
'Accelerating the development of sustainable innovations that appeal to
consumers and ensuring superior quality for our products throughout the
world are key factors for Henkel's success,' comments Professor Thomas
Müller-Kirschbaum, Head of Global Research and Development in Henkel's
Laundry and Home Care business sector. 'Compound screening with our partner
4SC Discovery also lets us subject a much higher volume of substances to
testing during the early stages of product development than has previously
been possible.'
Ends
About Henkel
Henkel operates worldwide with leading brands and technologies in three
business areas: Laundry&Home Care, Cosmetics/Toiletries and Adhesive
Technologies. Founded in 1876, Henkel holds globally leading market
positions both in the consumer and industrial businesses with well-known
brands such as Persil, Schwarzkopf and Loctite. Henkel employs more than
47,000 people and reported sales of 15,605 million euros and adjusted
operating profit of 2,029 million euros in fiscal 2011. Henkel's preferred
shares are listed in the German stock index DAX and the company ranks among
the Fortune Global 500.
About 4SC Discovery GmbH
4SC Discovery GmbH is a wholly-owned subsidiary of 4SC AG that offers
technologies and tailored research services covering drug discovery and
chemical optimisation through to a preclinical development candidate. The
company focuses its services on offering customers in the pharmaceutical,
biotech and chemical industries the cost and time-to-market benefits that
result from a drug discovery and optimisation process based on a powerful,
computer-aided, screening and discovery platform. In addition, 4SC
Discovery also applies its comprehensive pharmacological expertise to
investigating new compounds in the areas of cancer and autoimmune disease -
a measure also intended to further enhance the clinical development
pipeline for the 4SC Group. The company aims to engage in partnerships with
pharmaceutical and biotech companies to accelerate the development of these
research programmes and further advance their commercialisation.
About 4SC Group
The Group managed by 4SC AG (ISIN DE0005753818, Frankfurt Prime Standard:
VSC) discovers and develops targeted small-molecule drugs for the treatment
of diseases with a high unmet medical need in various autoimmune and cancer
indications. These drugs are intended to provide patients with innovative
treatment options that are more tolerable and efficacious than existing
therapies, and provide a better quality of life. At the end of 2011, 4SC
Group had 96 employees. The company was founded in 1997.
Legal Note
This document may contain projections or estimates relating to plans and
objectives relating to our future operations, products, or services; future
financial results; or assumptions underlying or relating to any such
statements; each of which constitutes a forward-looking statement subject
to risks and uncertainties, many of which are beyond our control. Actual
results could differ materially, depending on a number of factors.
For more information please visit www.4sc.com and www.4sc-discovery.com or
contact:
4SC AG
Jochen Orlowski, Investor Relations&Public Relations
jochen.orlowski(at)4sc.com, Tel.: +49 (0) 89 70 07 63 66
Bettina v. Klitzing-Stückle, Corporate Communications
bettina.von.klitzing(at)4sc.com, Tel.: +49 (0) 89 70 07 63 0
MC Services
Raimund Gabriel
raimund.gabriel(at)mc-services.eu , Tel.: +49 (0) 89 21 02 28 30
Mareike Mohr
mareike.mohr(at)mc-services.eu, Tel.: +49 (0) 89 21 02 28 40
The Trout Group (USA)
Chad Rubin
Crubin(at)troutgroup.com, Tel.: +1 646 378 2947
End of Corporate News
---------------------------------------------------------------------
02.04.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: 4SC AG
Am Klopferspitz 19a
82152 Martinsried
Germany
Phone: +49 (0)89 7007 63-0
Fax: +49 (0)89 7007 63-29
E-mail: public(at)4sc.com
Internet: www.4sc.de
ISIN: DE0005753818
WKN: 575381
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
163363 02.04.2012
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 02.04.2012 - 07:30 Uhr
Sprache: Deutsch
News-ID 130695
Anzahl Zeichen: 9338
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 288 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Press Release 4SC AG: Henkel and 4SC Discovery start research collaboration in compound screening"
steht unter der journalistisch-redaktionellen Verantwortung von
4SC AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
